Blood and Marrow Transplant (BMT), Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin
Conditions
Brief summary
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Detailed description
To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.
Interventions
Sponsors
National Institutes of Health (NIH)
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 61 Years
Healthy volunteers
No
Inclusion criteria
Morphologically confirmed relapsed non-Hodgkin's lymphoma Age: \>18 and \<61 years of age Signed informed consent
Exclusion criteria
Hepatic dysfunction defined by serum transaminases \>2.5X normal values Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min Diseases other than non-Hodgkin's lymphoma Prior bone marrow transplant procedure Severe psychological or medical illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
| Toxicity | — |
| Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of acute and chronic GVHD | — |
Countries
United States
Outcome results
None listed